Literature DB >> 20827778

Human parechoviruses in infants with systemic infection.

L Piñeiro1, D Vicente, M Montes, U Hernández-Dorronsoro, G Cilla.   

Abstract

Human parechoviruses (HPeVs) are RNA viruses related to neonatal sepsis, meningoencephalitis and other infections in young children. Little clinical and epidemiological information is available on these viruses. HPeVs were sought in cerebrospinal fluid from 397 infants aged less than 12 months from whom a sample was obtained to exclude meningitis or encephalitis from 2006 to 2009. HPeV infections were also tested in stool samples from 271 children aged less than 3 years old with gastroenteritis from November 2008 to March 2009. HPeV detection was by real-time polymerase chain reaction assay (region 5'UTR), followed by genotyping (region VP3/VP1). HPeVs were detected in the cerebrospinal fluid of nine infants (2.3%), one aged 6 months and eight aged 14-55 days old. All were admitted to hospital for febrile syndrome with abrupt clinical deterioration and suspected systemic infection without clear laboratory signs of meningeal inflammation. The same virus was detected in all the available nasopharyngeal aspirates, stool, and/or serum samples from each patient. At least eight of the nine cases were caused by HPeV3. HPeVs were detected in stool samples from 17 children (6.3%), the most prevalent types being types 1 and 3. In conclusion, HPeV infection is common in the Basque Country (Spain) and HPeV3 is a significant cause of hospital admission due to systemic infection in the first few months of life. In these patients, HPeVs should be investigated as part of routine tests for enterovirus. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20827778     DOI: 10.1002/jmv.21878

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

1.  Complete genome sequence of a novel type of human parechovirus strain reveals natural recombination events.

Authors:  Guangming Sun; Yong Wang; Gang Tao; Quan Shen; Weiping Cao; Xianlu Chang; Wen Zhang; Chen Shao; Miaoli Yi; Shihe Shao; Yan Yang
Journal:  J Virol       Date:  2012-08       Impact factor: 5.103

2.  Intracranial hemorrhage and other symptoms in infants associated with human parechovirus in Vienna, Austria.

Authors:  Herbert Kurz; Ruth Prammer; Wolfgang Bock; Robert Ollerieth; Günther Bernert; Karl Zwiauer; Judith H Aberle; Stephan W Aberle; Tamas Fazekas; Wolfgang Holter
Journal:  Eur J Pediatr       Date:  2015-06-25       Impact factor: 3.860

3.  Comparison of epidemiology and clinical characteristics of infections by human parechovirus vs. those by enterovirus during the first month of life.

Authors:  María Cabrerizo; Gloria Trallero; María José Pena; Amaia Cilla; Gregoria Megias; Carmen Muñoz-Almagro; Eva Del Amo; Diana Roda; Ana Isabel Mensalvas; Antonio Moreno-Docón; Juan García-Costa; Nuria Rabella; Manuel Omeñaca; María Pilar Romero; Sara Sanbonmatsu-Gámez; Mercedes Pérez-Ruiz; María José Santos-Muñoz; Cristina Calvo
Journal:  Eur J Pediatr       Date:  2015-05-16       Impact factor: 3.183

4.  Prevalence of human parechovirus and enterovirus in cerebrospinal fluid samples in children in Jinju, Korea.

Authors:  Ji-Hyun Seo; Jung Sook Yeom; Hee-Shang Youn; Tae-Hee Han; Ju-Young Chung
Journal:  Korean J Pediatr       Date:  2015-03-20

5.  Human parechovirus infections in patients admitted to hospital in Northern Italy, 2008-2010.

Authors:  Antonio Piralla; Milena Furione; Francesca Rovida; Antonietta Marchi; Mauro Stronati; Giuseppe Gerna; Fausto Baldanti
Journal:  J Med Virol       Date:  2012-04       Impact factor: 2.327

6.  Human parechovirus infection, Denmark.

Authors:  Thea K Fischer; Sofie Midgley; Camilla Dalgaard; Alex Y Nielsen
Journal:  Emerg Infect Dis       Date:  2014-01       Impact factor: 6.883

7.  Parechovirus infection preceding Guillain-Barré syndrome.

Authors:  Saara Linden; Tytti Vuorinen; Riikka Österback; Merja Soilu-Hänninen
Journal:  J Neurovirol       Date:  2012-05-12       Impact factor: 2.643

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.